Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Trace amine-associated receptor 1 regulation of methamphetamine-induced neurotoxicity.

Miner NB, Elmore JS, Baumann MH, Phillips TJ, Janowsky A.

Neurotoxicology. 2017 Dec;63:57-69. doi: 10.1016/j.neuro.2017.09.006. Epub 2017 Sep 15.

PMID:
28919515
2.

Serotonin in the Frontal Cortex: A Potential Therapeutic Target for Neurological Disorders.

Lu H, Liu QS.

Biochem Pharmacol (Los Angel). 2017 Feb;6(1). pii: e184. doi: 10.4172/2167-0501.1000e184. Epub 2016 Dec 29. No abstract available.

3.

Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-analysis.

Ashok AH, Mizuno Y, Volkow ND, Howes OD.

JAMA Psychiatry. 2017 May 1;74(5):511-519. doi: 10.1001/jamapsychiatry.2017.0135. Review.

4.

Neuronal Stress and Injury Caused by HIV-1, cART and Drug Abuse: Converging Contributions to HAND.

Sanchez AB, Kaul M.

Brain Sci. 2017 Feb 23;7(3). pii: E25. doi: 10.3390/brainsci7030025. Review.

5.

Enhanced sensitivity to drugs of abuse and palatable foods following maternal overnutrition.

Peleg-Raibstein D, Sarker G, Litwan K, Krämer SD, Ametamey SM, Schibli R, Wolfrum C.

Transl Psychiatry. 2016 Oct 4;6(10):e911. doi: 10.1038/tp.2016.176.

6.

Self-reported attentional and motor impulsivity are related to age at first methamphetamine use.

Cservenka A, Ray LA.

Addict Behav. 2017 Feb;65:7-12. doi: 10.1016/j.addbeh.2016.09.008. Epub 2016 Sep 28.

PMID:
27701027
7.

Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.

Kish SJ, Boileau I, Callaghan RC, Tong J.

Eur J Neurosci. 2017 Jan;45(1):58-66. doi: 10.1111/ejn.13363. Epub 2016 Sep 5. Review.

PMID:
27519465
8.

Heightened Dopaminergic Response to Amphetamine at the D3 Dopamine Receptor in Methamphetamine Users.

Boileau I, Payer D, Rusjan PM, Houle S, Tong J, McCluskey T, Wilson AA, Kish SJ.

Neuropsychopharmacology. 2016 Dec;41(13):2994-3002. doi: 10.1038/npp.2016.108. Epub 2016 Jun 29.

9.

Methamphetamine alters microglial immune function through P2X7R signaling.

Fernandes NC, Sriram U, Gofman L, Cenna JM, Ramirez SH, Potula R.

J Neuroinflammation. 2016 Apr 26;13(1):91. doi: 10.1186/s12974-016-0553-3.

10.

Fragment C Domain of Tetanus Toxin Mitigates Methamphetamine Neurotoxicity and Its Motor Consequences in Mice.

Mendieta L, Granado N, Aguilera J, Tizabi Y, Moratalla R.

Int J Neuropsychopharmacol. 2016 Aug 12;19(8). pii: pyw021. doi: 10.1093/ijnp/pyw021. Print 2016 Aug.

11.

Methamphetamine addiction: involvement of CREB and neuroinflammatory signaling pathways.

Krasnova IN, Justinova Z, Cadet JL.

Psychopharmacology (Berl). 2016 May;233(10):1945-62. doi: 10.1007/s00213-016-4235-8. Epub 2016 Feb 12. Review.

12.

Specificity and impact of adrenergic projections to the midbrain dopamine system.

Mejias-Aponte CA.

Brain Res. 2016 Jun 15;1641(Pt B):258-73. doi: 10.1016/j.brainres.2016.01.036. Epub 2016 Jan 26. Review.

13.

Apocynin prevents mitochondrial burdens, microglial activation, and pro-apoptosis induced by a toxic dose of methamphetamine in the striatum of mice via inhibition of p47phox activation by ERK.

Dang DK, Shin EJ, Nam Y, Ryoo S, Jeong JH, Jang CG, Nabeshima T, Hong JS, Kim HC.

J Neuroinflammation. 2016 Jan 18;13:12. doi: 10.1186/s12974-016-0478-x.

14.

Extended access to methamphetamine self-administration up-regulates dopamine transporter levels 72 hours after withdrawal in rats.

D'Arcy C, Luevano JE, Miranda-Arango M, Pipkin JA, Jackson JA, Castañeda E, Gosselink KL, O'Dell LE.

Behav Brain Res. 2016 Jan 1;296:125-128. doi: 10.1016/j.bbr.2015.09.010. Epub 2015 Sep 12.

15.

Effectiveness of Electroconvulsive Therapy in Persistent Methamphetamine Psychosis: A Pilot Study.

Ziaaddini H, Roohbakhsh T, Nakhaee N, Ghaffari-Nejad A.

Addict Health. 2015 Winter-Spring;7(1-2):14-23.

16.

Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence.

Boileau I, McCluskey T, Tong J, Furukawa Y, Houle S, Kish SJ.

Neuropsychopharmacology. 2016 Mar;41(4):1179-87. doi: 10.1038/npp.2015.267. Epub 2015 Aug 31.

17.

Characterization of binge-dosed methamphetamine-induced neurotoxicity and neuroinflammation.

McConnell SE, O'Banion MK, Cory-Slechta DA, Olschowka JA, Opanashuk LA.

Neurotoxicology. 2015 Sep;50:131-41. doi: 10.1016/j.neuro.2015.08.006. Epub 2015 Aug 15.

18.

Gray-matter volume, midbrain dopamine D2/D3 receptors and drug craving in methamphetamine users.

Morales AM, Kohno M, Robertson CL, Dean AC, Mandelkern MA, London ED.

Mol Psychiatry. 2015 Jun;20(6):764-71. doi: 10.1038/mp.2015.47. Epub 2015 Apr 21.

19.

Monoamine reuptake inhibitors in Parkinson's disease.

Huot P, Fox SH, Brotchie JM.

Parkinsons Dis. 2015;2015:609428. doi: 10.1155/2015/609428. Epub 2015 Feb 25. Review.

20.

Methamphetamine effects on blood-brain barrier structure and function.

Northrop NA, Yamamoto BK.

Front Neurosci. 2015 Mar 4;9:69. doi: 10.3389/fnins.2015.00069. eCollection 2015. Review.

Supplemental Content

Support Center